Loading
companiesCompany
Threshold Pharmaceuticals
Threshold developed evofosfamide, a drug switched on only in the oxygen-starved parts of tumours; two phase 3 trials in pancreatic cancer and sarcoma failed in 2015 and the company merged away.
Also called: Threshold Pharmaceuticals, Inc.
Overview
Threshold Pharmaceuticals, founded in 2001 in San Francisco, pursued hypoxia-activated prodrugs, chiefly evofosfamide (TH-302), a bromo-isophosphoramide mustard released in hypoxic tumour tissue and partnered with Merck KGaA. The MAESTRO trial in pancreatic cancer and the TH CR-406 trial in soft tissue sarcoma both missed their survival endpoints in 2015; Threshold later merged with Molecular Templates. Its trials remain on ClinicalTrials.gov under Threshold as lead sponsor.
Headquarters
San Francisco, CA, US
Scorecard
All companies#452of 1244 companies, score 7
- modalities +2
- registry trials +8
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 15 registry studies. Formula on the scorecards page.
Type
Stage
Wound down
Website
Founded
2001
NegativeHypoxia-activated prodrug (small molecule alkylating agent)
Evofosfamide was the most advanced hypoxia-activated drug, designed to kill the oxygen-starved tumour cells radiotherapy and chemotherapy miss, but it failed both of its phase 3 trials in 2015.
Similar pages
- CompanyLisata Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyPTC Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST).
- CompanyPregLem
- CompanyMedigene
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyAgennix
- CompanyImmunitor
- CompanyMerrimack Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyEmergent BioSolutions
cancers
technologies
drugs
NegativeHypoxia-activated prodrug (small molecule alkylating agent)